192 results on '"PANNEE JOSEF"'
Search Results
2. Induction of Amyloid-β42 Production by Fipronil and Other Pyrazole Insecticides
3. Abeta CSF LC-MS
4. Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species
5. CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation
6. Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry
7. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum
8. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
9. Multiplexing and multivariate analysis in neurodegeneration
10. Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70
11. SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration
12. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements
13. Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
14. Plasma Aβ ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
15. Reference measurement procedures for Alzheimerʼs disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42
16. Plasma metabolomics of presymptomatic PSEN1 ‐H163Y mutation carriers: a pilot study
17. The global Alzheimer's Association round robin study on plasma amyloid β methods
18. Ultra‐performance liquid chromatography‐tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture
19. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
20. Plasma metabolomics of presymptomatic PSEN1-H163Y mutation carriers: A pilot study
21. Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults.
22. P4-473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX Aβ PEPTIDES IN HUMAN CEREBROSPINAL FLUID
23. F1‐05‐03: THE 1946 COHORT: RELATIONSHIPS BETWEEN CEREBRAL AMYLOID PATHOLOGY USING TWO INDEPENDENT METHODS FOR PLASMA AMYLOID BETA MEASUREMENT
24. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ 42 IN HUMAN CEREBROSPINAL FLUID
25. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements
26. Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases
27. Additional file 2: Figure S2. of Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
28. CERTIFICATION REPORT: The certification of Amyloid β1-42 in CSF in ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC
29. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update
30. USE FOR CALIBRATION OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42
31. [P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‐AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS
32. PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1-42
33. Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure
34. Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
35. Mass spectrometric quantification of amyloid-beta in cerebrospinal fluid and plasma
36. Tracking reactive astrocytes in autosomal dominant Alzheimer disease with plasma GFAP and multi‐modal PET imaging.
37. Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases.
38. The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease
39. TOWARD RE-CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID
40. A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX Aβ PEPTIDES IN HUMAN CEREBROSPINAL FLUID
41. THE 1946 COHORT: RELATIONSHIPS BETWEEN CEREBRAL AMYLOID PATHOLOGY USING TWO INDEPENDENT METHODS FOR PLASMA AMYLOID BETA MEASUREMENT
42. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
43. Specific Triazine Herbicides Induce Amyloid-β42 Production
44. Reference measurement procedure for CSF amyloid beta (Aβ)1-42and the CSF Aβ1-42/Aβ1-40ratio - a cross-validation study against amyloid PET
45. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study
46. P4-313: Commutability of the Candidate Certified Reference Materials for the Standardization of Aβ1-42 Measurements in Human Cerebrospinal Fluid
47. Improved concordance between [11C]PIB PET and CSF Aβ42 using Aβ42/Aβ40: findings from a multicentre European memory clinic population
48. Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements
49. Round robin test on quantification of amyloid‐β 1–42 in cerebrospinal fluid by mass spectrometry
50. P4-231: Commutability of candidate reference materials for the harmonization of Aβ1-42 measurements, on behalf of the ifcc working group on CSF proteins
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.